Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruxo-BEAT Trial
2024-515619-23-00Phase 2Authorised
- Sponsor
- University Hospital RWTH Aachen
- Start
- Jun 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of ruxolitinib in polycythemia vera (PV) and thrombocythemia (2 arms), sponsored by University Hospital RWTH Aachen. Primary endpoint: Complete clinicohematologic response rate at month 6. Planned start Jun 2015; status: authorised.
02
Drugs
03
Conditions
polycythemia vera (PV)thrombocythemia
Beyond the preview
Go deeper on 2024-515619-23-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515619-23-00.